Quick Answer
Inhibitor Therapeutics, Inc. reported Operating Income Loss of -$3.43 million for the year ending 2025.
- Inhibitor Therapeutics, Inc. showed an increase of +6.3% in Operating Income Loss from 2024 to 2025.
- This data is from Inhibitor Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2012: -$137.5 thousand | Q1 2013: -$90.5 thousand | Q2 2013: -$403.6 thousand | Q3 2013: -$1.29 million | Q1 2014: -$186.9 thousand | Q2 2014: -$2.12 million | Q3 2014: -$738.1 thousand | Q1 2015: -$922.7 thousand | Q2 2015: -$791.7 thousand | Q3 2015: -$1.20 million | Q1 2016: -$1.19 million | Q2 2016: -$1.33 million | Q3 2016: -$1.73 million | Q1 2017: -$2.81 million | Q2 2017: -$719.4 thousand | Q3 2017: -$681.2 thousand | Q1 2018: -$1.17 million | Q2 2018: -$884.4 thousand | Q3 2018: -$1.18 million | Q1 2019: -$791.6 thousand | Q2 2019: -$635.5 thousand | Q3 2019: -$682.9 thousand | Q1 2020: -$385.4 thousand | Q2 2020: -$315.0 thousand | Q3 2020: -$302.8 thousand | Q1 2021: -$167.8 thousand | Q2 2021: -$62.6 thousand | Q3 2021: -$66.2 thousand | Q1 2022: -$93.5 thousand | Q2 2022: -$70.8 thousand | Q3 2022: -$70.0 thousand | Q1 2023: -$629.7 thousand | Q2 2023: -$742.5 thousand | Q3 2023: -$759.5 thousand | Q1 2024: -$774.8 thousand | Q2 2024: -$585.1 thousand | Q3 2024: -$813.2 thousand | Q1 2025: -$674.6 thousand | Q2 2025: -$695.8 thousand | Q3 2025: -$741.2 thousand.
- Over the full 14 years of available data (2012 to 2025), Inhibitor Therapeutics, Inc.'s Operating Income Loss has declined by 511.2%.
- Historical annual values: Fiscal year 2025: -$3.43 million | Fiscal year 2024: -$3.66 million | Fiscal year 2023: -$3.40 million | Fiscal year 2022: -$657.9 thousand | Fiscal year 2021: -$325.4 thousand | Fiscal year 2020: -$1.06 million | Fiscal year 2019: -$2.75 million | Fiscal year 2018: -$4.56 million | Fiscal year 2017: -$5.12 million | Fiscal year 2016: -$7.02 million | Fiscal year 2015: -$3.95 million | Fiscal year 2014: -$3.94 million | Fiscal year 2013: -$2.00 million | Fiscal year 2012: -$560.7 thousand.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: